drugset / Trial / NCT00005820

Nitrocamptothecin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy

NCT00005820 ↗

NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of nitrocamptothecin in treating men who have stage IV prostate cancer that has not responded to hormone therapy.

Timeline

Start
2000-05
Primary completion
2004-09
Completion
2006-09

Drugs

EvaluationDrugModalityDoseRoute
Subject nitrocamptothecin Unknown 1.5 mg/m2 Oral

Indications